Martin Austin joined Ventac Partners as Partner in September 2010. He has more than 35 years of senior executive experience in the pharmaceutical industry, including the position as Head of Business Development for the Pharmaceuticals Division at Hoffmann-La Roche, in the international investment community as a Principal at Paul Capital Partners Royalty Funds, a USA based specialist in Secondary Private Equity and Alternative Asset Investments, as well as from advising multiple SME’s in the life sciences arena. Areas of expertise include business analysis, business planning and competitive intelligence functions, M&A, equity investments, product divestments, and in- and out-licensing on a broad international scale. Since 2005, Martin Austin has been Managing Director of TransformRx GmbH providing business advice to clients regarding investment and business development.
He is the author of “Business Development for the Biotechnology and Pharmaceutical Industry” 2008 based on the courses he presents with CELforpharma (Brussels), Pharmaguys (Beijing), and at Basel University as a part of the Masters in Drug Development Sciences degree course and presents an elective course in the Masters program at HEC Paris. He has a second book in preparation derived from courses performed for the World Intellectual Property Organisation of the United Nations
Martin Austin is a Partner in MarraM Advisors sarl, an Investment and Fund Governance firm which is the sponsor of the BioIndustrial Finance Fund (in formation), and MarraM BioMass which is developing projects in microalgal oil production.
Martin Austin also serves as a Board Member of RSA AG the Swiss subsidiary of the RSA Group, as a Board Invitee at Neuroscience Technologies in Barcelona, and is Chairman of Zestagen SA in Lausanne.